Association between depth of response and survival in patients with advanced‐stage non–small cell lung cancer treated with first‐line chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Association between depth of response and survival in patients with advanced‐stage non–small cell lung cancer treated with first‐line chemotherapy

Published:2019-04 Issue:14 Volume:125 Page:2394-2399
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Morgensztern Daniel¹,Ko Amy²,O’Brien Mary³,Ong Teng Jin²,Waqar Saiama N.¹,Socinski Mark A.⁴,Postmus Pieter E.⁵,Bhore Rafia²

Affiliation:

1. Washington University School of Medicine St. Louis Missouri

2. Celgene Corporation Summit New Jersey

3. Royal Marsden NHS Foundation Trust London United Kingdom

4. Florida Hospital Cancer Institute Orlando Florida

5. Leiden University Leiden the Netherlands

Funder

Celgene

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32114

Reference23 articles.

1. The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology

2. Overall Survival: A Gold Standard in Search of a Surrogate

3. New Guidelines to Evaluate the Response to Treatment in Solid Tumors

4. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

5. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune‐inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer receiving first‐line immunotherapy;Thoracic Cancer;2024-08-27

2. A bootstrapping method to optimize go/no‐go decisions from single‐arm, signal‐finding studies in oncology;CPT: Pharmacometrics & Systems Pharmacology;2024-06-11

3. Statistical Interpretation and Comparison of Waterfall Plots;JCO Clinical Cancer Informatics;2023-09

4. Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?;American Society of Clinical Oncology Educational Book;2023-05

5. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer;Anticancer Research;2023-01-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3